Phaseline

Targets › ATP2A2

ATP2A2 (Sarcoplasmic/endoplasmic reticulum calcium ATPase 2): drug programs, companies and trials

2 programs from 1 company in 3 trials: 3 Phase 1; Cardiovascular; next expected readout Oct 2027.

This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen. Involved in autophagy in response to starvation. (UniProt, P16615)

Open in Phaseline: the race on ATP2A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SardocorSRD-001
AAV1-mediated SERCA2a gene therapy for SERCA2a enzyme replacement
ATP2A2Phase 1DMD-Associated Dilated Cardiomyopathy; Congestive Heart FailureOct 2027
SardocorAAV1/SERCA2a
Adeno-associated virus serotype 1 (AAV1) delivering SERCA2a gene to enhance cardiac calciu
ATP2A2Phase 1Heart Failure, DiastolicAug 2029

Conditions

DMD-Associated Dilated Cardiomyopathy (1) Congestive Heart Failure (1) Heart Failure, Diastolic (1)

Modalities

protein or peptide (1), other (1)

Companies

Sardocor (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.